ACAM-FLU-A: Difference between revisions
m Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}) |
m Changes made per Mahshid's request |
||
Line 14: | Line 14: | ||
[[Category:Influenza vaccines]] | [[Category:Influenza vaccines]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 16:15, 18 September 2017
WikiDoc Resources for ACAM-FLU-A |
Articles |
---|
Most recent articles on ACAM-FLU-A |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on ACAM-FLU-A at Clinical Trials.gov Clinical Trials on ACAM-FLU-A at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on ACAM-FLU-A
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on ACAM-FLU-A Discussion groups on ACAM-FLU-A Patient Handouts on ACAM-FLU-A Directions to Hospitals Treating ACAM-FLU-A Risk calculators and risk factors for ACAM-FLU-A
|
Healthcare Provider Resources |
Causes & Risk Factors for ACAM-FLU-A |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
ACAM-FLU-A is a vaccine, being developed by Acambis, which is intended to provide lifelong protection against all strains of Influenza A. The vaccine targets the M2 protein which is found on the surface of all strains of Influenza A.
The vaccine has been tested in a human trial, in the United States, where it is claimed to have successfully protected 90% of individuals against the flu virus. Further human trials are planned. [1]